Function of sigma1 receptors in Parkinson's disease

Objective –  The objective of this study was to investigate the mapping of sigma1 receptors in Parkinson's disease (PD) using [11C]SA4503 and positron emission tomography (PET), and to assess whether sigma1 receptors are involved in the damaged dopaminergic system in PD patients.

[1]  K. Matsuno,et al.  Sigma 1 receptor subtype is involved in the relief of behavioral despair in the mouse forced swimming test. , 1996, European journal of pharmacology.

[2]  Ulla Ruotsalainen,et al.  Increased density of dopamine D2 receptors in the putamen, but not in the caudate nucleus in early Parkinson's disease: a PET study with [11C]raclopride , 1995, Journal of the Neurological Sciences.

[3]  M. Senda,et al.  In vivo evaluation of [(11)C]SA4503 as a PET ligand for mapping CNS sigma(1) receptors. , 2000, Nuclear medicine and biology.

[4]  Kiichi Ishiwata,et al.  In vivo evaluation of [11C]SA4503 as a PET ligand for mapping CNS sigma1 receptors , 2000 .

[5]  A. Urani,et al.  The interaction between neuroactive steroids and the σ1 receptor function: behavioral consequences and therapeutic opportunities , 2001, Brain Research Reviews.

[6]  H Orihara,et al.  Performance evaluation of a large axial field-of-view PET scanner: SET-2400W , 1997, Annals of nuclear medicine.

[7]  S. Chaki,et al.  Regulation of NMDA-induced [3H] dopamine release from rat hippocampal slices through sigma-1 binding sites , 1998, Neurochemistry International.

[8]  K. Ishiwata,et al.  Age-related changes of the binding of [3H]SA4503 to sigma1 receptors in the rat brain , 2003, Annals of nuclear medicine.

[9]  R. Baldessarini,et al.  (+)-6,7-Benzomorphan sigma ligands stimulate dopamine synthesis in rat corpus striatum tissue , 1991, Brain Research.

[10]  Hideo Tsukada,et al.  An increase of sigma1 receptors in the aged monkey brain , 2003, Neurobiology of Aging.

[11]  A J Lees,et al.  What features improve the accuracy of clinical diagnosis in Parkinson's disease: A clinicopathologic study , 2001, Neurology.

[12]  V. Sossi,et al.  In vivo positron emission tomographic evidence for compensatory changes in presynaptic dopaminergic nerve terminals in Parkinson's disease , 2000, Annals of neurology.

[13]  T Sasaki,et al.  Intrasubject correlation between static sean and distribution volume images for [11C]flumazenil PET , 2000, Annals of nuclear medicine.

[14]  I. Guillemain,et al.  Immunocytochemical localization of the sigma1 receptor in the adult rat central nervous system , 2000, Neuroscience.

[15]  W. Bowen.  Sigma receptors: recent advances and new clinical potentials. , 2000, Pharmaceutica acta Helvetiae.

[16]  W. Bowen,et al.  Sigma receptors: biology and function. , 1990, Pharmacological reviews.

[17]  K. Någren,et al.  PET examination of the monoamine transporter with [11c]β‐CIT and [11c]β‐CFT in early parkinson's disease , 1995 .

[18]  Tetsuya Kobayashi,et al.  σ1 Receptor subtype is involved in the relief of behavioral despair in the mouse forced swimming test , 1996 .

[19]  M. Senda,et al.  Efficient HPLC separation of [11C]β-CFT or [11C]β-CIT from an N-desmethyl precursor on a semipreparative reversed phase ODS column , 2000 .

[20]  V Kaasinen,et al.  Upregulation of putaminal dopamine D2 receptors in early Parkinson's disease: a comparative PET study with [11C] raclopride and [11C]N-methylspiperone. , 2000, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[21]  S. Lewis,et al.  Biomarkers and Parkinson's disease. , 2004, Brain : a journal of neurology.

[22]  E. Montgomery,et al.  Issues in the early diagnosis of Parkinson's disease , 1997, Neurology.

[23]  D J Brooks,et al.  Regional changes in [18F]dopa metabolism in the striatum in Parkinson's disease. , 1996, Brain : a journal of neurology.

[24]  W. Bowen,et al.  A proposal for the classification of sigma binding sites. , 1992, Trends in pharmacological sciences.

[25]  L. Werling,et al.  Regulation of [3H]dopamine release from rat striatal slices by sigma receptor ligands. , 1994, The Journal of pharmacology and experimental therapeutics.

[26]  Philippe Hantraye,et al.  Dopaminergic function and dopamine transporter binding assessed with positron emission tomography in Parkinson disease. , 2002, Archives of neurology.

[27]  K. Någren,et al.  PET examination of the monoamine transporter with [11C]beta-CIT and [11C]beta-CFT in early Parkinson's disease. , 1995, Synapse.

[28]  W. Dauer,et al.  Parkinson's Disease Mechanisms and Models , 2003, Neuron.

[29]  P. Lipton,et al.  σ-Ligands and non-competitive NMDA antagonists inhibit glutamate release during cerebral ischemia , 1990, Neuroscience Letters.

[30]  M. Senda,et al.  An alternative synthesis of [11C]raclopride for routine use , 1999, Annals of nuclear medicine.

[31]  I. Guillemain,et al.  Immunocytochemical localization of the sigma(1) receptor in the adult rat central nervous system. , 2000, Neuroscience.

[32]  M. Senda,et al.  Mapping of sigma1 receptors in living human brain , 2001, NeuroImage.

[33]  A. Bonnet,et al.  [The Unified Parkinson's Disease Rating Scale]. , 2000, Revue neurologique.

[34]  S. Gilman,et al.  Diagnostic criteria for Parkinson disease. , 1999, Archives of neurology.

[35]  Hideo Tsukada,et al.  Mapping of CNS sigma1 receptors in the conscious monkey: Preliminary PET study with [11C]SA4503 , 2001, Synapse.